ArticleFrontiers in pharmacology2026
IR-780 improves urination function and complications in rats with partial bladder outlet obstruction by protecting bladder smooth muscle cell mitochondria from oxidative stress.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Partial bladder outlet obstruction (pBOO) is the most common cause of lower urinary tract symptoms (LUTS). Prolonged BOO induces bladder remodeling, which can lead to severe bladder dysfunction and refractory LUTS in some patients, even after obstruction resolution. This condition significantly impairs patients' quality of life, and no effective treatment is currently available. This study investigated a pBOO rat model using IR-780, a novel near-infrared lipophilic dye with potential targeted antioxidant effects. Methods: A partial ligation of the rat bladder neck was performed to establish a pBOO model. After confirming successful modeling, the rats were randomly divided into sham, sham + IR-780, pBOO, and pBOO + IR-780 groups (eight rats per group). One week post-surgery, rats received intraperitoneal injections of IR-780 (0.667 mg/kg) or an equivalent volume of phosphate buffered saline solution twice weekly for 3 weeks. Before evaluating efficacy using the bladder filling manometry method, we examined the distribution of IR-780 in tissues and subcellular compartments Results: IR-780 accumulated at high levels in the bladders of rats with pBOO, where it was primarily taken up by bladder smooth muscle cells (BSMCs) and localized within the mitochondria. Bladder pressure measurements revealed that IR-780 significantly improved bladder function in rats with pBOO. IR-780 effectively mitigated pathological changes in bladder smooth muscle tissue and concurrently alleviated pBOO-induced reflux nephropathy. Conclusion: IR-780 improved urinary function and complications in rats with pBOO by protecting BSMC mitochondria from oxidative stress, which was potentially mediated through the activation of the Nrf2 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.